Mahmoud et al. reported that 60 invasive urothelial carcinomas were immunostained for FGFR2 and FGFR3 and found that the higher the grade, the higher the FGFR2 positivity rate (p = 0.044) and the more advanced the disease, the higher the FGFR2 positivity rate (p = 0.048) [31]. This evidence concerns the gene FGFR2 and urothelial carcinoma.